UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): May 15, 2008
(Exact name of registrant as specified in charter)
| Utah | 000-26753 | 87-0416131 |
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) |
43 West 33rd Street
New York, New York 10001
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 695-3334
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
As previously announced, on May 4, 2008, shareholders holding a majority of the outstanding shares of common stock of Amazon Biotech, Inc. (the “Company”) terminated Simcha Edell and Mechael Kanovsky as directors of the Company (the “Terminated Directors”). The Terminated Directors had previously submitted resignation as executive officers of the Company. Eliyahu BenTal Tolchinsky was appointed by the majority shareholders as director of the Company and was appointed as the Chief Executive Officer and President of the Company. On May 14, 2008, Mr. Kanovsky, the former Chief Executive Officer, filed a Form 8K with the Securities and Exchange Commission challenging the validity of the removal of the Terminated Directors and the resignation of the executive officers. The filing of this Form 8K by Mr. Kanovsky was not valid and was not authorized by the management of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | AMAZON BIOTECH, INC. | |
| | | | |
| Date: May 15, 2008 | By: | /s/ Eliyahu BenTal Tolchinsky | |
| | | Name: Eliyahu Bental Tolchinsky | |
| | | Title: CEO | |
| | | | |
